|
Age at ESRD onset, Median (IQR)
|
66.0 (53.0, 75.0)
|
60.0 (48.0, 70.0)
|
68.0 (57.0, 76.0)
|
64.0 (52.0, 74.0)
|
|
Age group, n (%)
|
|
18- < 45
|
412 (13.8)
|
141 (19.1)
|
165 (11.0)
|
106 (14.2)
|
|
45- < 65
|
987 (33.1)
|
307 (41.7)
|
406 (27.1)
|
274 (36.7)
|
|
65- < 75
|
830 (27.8)
|
170 (23.1)
|
473 (31.5)
|
187 (25.0)
|
|
75+
|
756 (25.3)
|
119 (16.2)
|
457 (30.5)
|
180 (24.1)
|
|
Males, n (%)
|
1777 (59.5)
|
477 (64.7)
|
877 (58.4)
|
423 (56.6)
|
|
Race, n (%)
|
|
White
|
2689 (90.1)
|
667 (90.5)
|
1360 (90.6)
|
662 (88.6)
|
|
Black
|
163 (5.5)
|
39 (5.3)
|
76 (5.1)
|
48 (6.4)
|
|
Other
|
133 (4.5)
|
31 (4.2)
|
65 (4.3)
|
37 (5.0)
|
|
Charlson score, median (IQR)
|
7.0 (5.0, 9.0)
|
6.0 (4.0, 8.0)
|
7.0 (5.0, 9.0)
|
7.0 (5.0, 9.0)
|
|
Charlson score 8 or more, n (%)
|
1210 (40.5)
|
221 (30.0)
|
684 (45.6)
|
305 (40.8)
|
|
Primary cause of ESRD, n (%)
|
|
Diabetes
|
1073 (36.0)
|
231 (31.3)
|
552 (36.8)
|
290 (38.8)
|
|
Hypertension
|
621 (20.8)
|
148 (20.1)
|
323 (21.5)
|
150 (20.1)
|
|
Glomerulonephritis
|
451 (15.1)
|
127 (17.2)
|
214 (14.3)
|
110 (14.7)
|
|
Infiltrative diseases
|
180 (6.0)
|
41 (5.6)
|
92 (6.1)
|
47 (6.3)
|
|
Cystic kidney
|
87 (2.9)
|
35 (4.8)
|
35 (3.8)
|
17 (2.3)
|
|
Health care utilization
|
|
Total Follow-up (person years)
|
8440.7
|
1806.2
|
4394.1
|
2240.4
|
|
Primary Care Visits (ppy)
|
4.5
|
.6
|
4.9
|
6.9
|
|
Other Specialty Visits (ppy)
|
9.1
|
8.0
|
10.0
|
8.1
|
|
Mid-level/Nephrology Visits (ppy)
|
2.8
|
4.0
|
3.4
|
0.6
|
|
Hospital Admissions (ppy)
|
2.2
|
1.8
|
2.3
|
2.2
|
|
ED visits (ppy)
|
1.5
|
1.2
|
1.6
|
1.6
|
|
Outcomes
|
|
Transplant, n (% at 4 years)
|
605 (20.3%)
|
232 (31.5%)
|
251 (16.7%)
|
122 (16.3%)
|
|
Died, n (% at 4 years)
|
1444 (48.4%)
|
272 (36.9%)
|
775 (51.6%)
|
397 (51.3%)
|
|
Median Survival years (IQR)
|
4.1 (2.6, 6.7)
|
4.3 (2.3, 7.0)
|
4.1 (2.0, 6.4)
|
3.9 (2.0, 7.0)
|
